Claudin-4 Protein-VLP, Human, Recombinant

Claudin-4 (CLDN4) is a key component of tight junctions (TJs) in epithelial cells. CLDN4 is overexpressed in many epithelial malignancies and correlates with cancer progression. Changes in CLDN4 expression have been associated with epigenetic factors (such as hypomethylation of promoter DNA), inflammation associated with infection and cytokines, and growth factor signaling. CLDN4 helps to maintain the tumor microenvironment by forming TJs and acts as a barrier to the entry of anticancer drugs into tumors.

Pack Size	Availability	Price/USD
100 μg	5 days	$ 1,620.00
500 μg	5 days	$ 6,520.00
1 mg	5 days	$ 10,870.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 1,620.00

500 μg

5 days

$ 6,520.00

1 mg

5 days

$ 10,870.00

Description

Species	Human
Expression System	HEK293
Accession Number	O14493
Synonyms	Claudin4, CLDN4, Claudin-4, CPETR1, CPE-R, WBSCR8, CPE R
Construction	Recombinant Human Claudin 4 Protein-VLP is expressed from HEK293. It contains Met1-Val209.[Accession \|O14493]
Protein Purity	> 95% as determined by HPLC
Molecular Weight	The target protein has a predicted MW of 23.31 kDa.

Endotoxin	Less than 1EU per μg by the LAL method.
Formulation	Supplied as 0.22μm filtered solution in PBS (pH 7.4).Notice: If you need it for immunization, Do Not use any adjuvant.
Stability & Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	Claudin-4 (CLDN4) is a key component of tight junctions (TJs) in epithelial cells. CLDN4 is overexpressed in many epithelial malignancies and correlates with cancer progression. Changes in CLDN4 expression have been associated with epigenetic factors (such as hypomethylation of promoter DNA), inflammation associated with infection and cytokines, and growth factor signaling. CLDN4 helps to maintain the tumor microenvironment by forming TJs and acts as a barrier to the entry of anticancer drugs into tumors.